BioMarin Pharmaceutical Inc.  

(Public, NASDAQ:BMRN)   Watch this stock  
Find more results for BMRN
86.84
-0.58 (-0.66%)
After Hours: 86.97 +0.13 (0.15%)
Mar 23, 4:15PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 86.69 - 87.90
52 week 73.45 - 102.49
Open 87.31
Vol / Avg. 792,355.00/1.13M
Mkt cap 15.08B
P/E     -
Div/yield     -
EPS -3.84
Shares 172.87M
Beta 1.62
Inst. own 105%
Feb 23, 2017
Q4 2016 Biomarin Pharmaceutical Inc Earnings Release (Estimated)
Jan 9, 2017
Biomarin Pharmaceutical Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin -26.23% -56.43%
Operating margin -29.86% -71.94%
EBITD margin - -8.71%
Return on average assets -8.03% -16.26%
Return on average equity -11.67% -24.39%
Employees 2,293 -
CDP Score - -

Address

105 Digital Dr
NOVATO, CA 94949-8703
United States - Map
+1-415-5066700 (Phone)
+1-415-3827889 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.

Officers and directors

Jean-Jacques Bienaime Chairman of the Board, Chief Executive Officer
Age: 62
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Daniel Keith Spiegelman Chief Financial Officer, Executive Vice President
Age: 57
Bio & Compensation  - Reuters
G. Eric Davis Executive Vice President, General Counsel, Secretary
Age: 45
Bio & Compensation  - Reuters
Jeff Robert Ajer Executive Vice President, Chief Commercial Officer
Age: 54
Bio & Compensation  - Reuters
Robert A. Baffi Ph.D. Executive Vice President - Technical Operations
Age: 61
Bio & Compensation  - Reuters
Henry J. Fuchs M.D.,Ph.D. Executive Vice President and Chief Medical Officer
Age: 58
Bio & Compensation  - Reuters
Brian R. Mueller Group Vice President, Corporate Controller, Chief Accounting Officer
Age: 42
Bio & Compensation  - Reuters
Richard A. Meier Lead Independent Director
Age: 56
Bio & Compensation  - Reuters
Willard H. Dere M.D. Director
Age: 62
Bio & Compensation  - Reuters
Kathryn E. Falberg Director
Age: 55
Bio & Compensation  - Reuters